玮俊生物科技有限公司（00660）于2026年3月4日发布截至2026年2月28日的股份变动月报。公告显示，公司当前法定/注册股本包括普通股与可换股优先股，普通股法定/注册股本为100,000,000港元，优先股法定/注册股本为2,040,000港元，合计102,040,000港元，较上月无变化。
已发行股份方面，截至2月底，公司普通股数量为178,476,453股，报告期内无新增发行、回购或注销，库存股数量保持为0股。可换股优先股数量同样未发生变动。
根据公告，普通股购股权数量为15,954,685股，行使价为每股0.25港元，报告期内未有授出、行使或失效导致的股份增减。公司现行可换股债券本金分别为67,000,000港元、20,150,000港元、12,250,000港元及15,000,000港元，报告期内无转换活动。
截至2026年2月28日，公司股本保持不变。公司表示，所有证券发行及相关事宜均遵守香港联交所《上市规则》及有关法律规定。公告由执行董事林家俊签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.